But it is Epidiolex, GW's potential treatment for rare forms of childhood epilepsy such as Dravet Syndrome , which has attracted US investors this time round. The programme, which will be the sole beneficiary of the funds raised from the new share offering, received a boost in November when US regulators granted the progamme 'orphan status'. This designation is given to drugs which address diseases for which there is no existing treatment, and allows GW to start supplying the drug to a select number of patients to test its effectiveness.